Bone · 2025
Pain intensity in patients with genetic metabolic bone diseases: an observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morri Mattia, Tremosini Morena, Forni Cristiana, Pedrini Elena, Moroni Alice, Gnoli Maria, Di Cecco Alessia, Sangiorgi Luca
Аннотация
OBJECTIVE: The aim of this study was to describe the intensity of the pain in patients with genetic metabolic bone disease and to identify possible risk factors.
DESIGN: Retrospective cohort study.
SETTING: The patients were recruited through the outpatient register of the Centre for Rare Skeletal Diseases between 2017 and 2022 from a dedicated orthopedic hospital in northern Italy.
SUBJECTS: All patients with a diagnosis of genetic metabolic bone disease were enrolled. The diagnosis of the pathology was based on the clinical data and the outcome of any genetic tests.
METHODS: Pain intensity (0-10) at the first exam was collected and two comparison groups were made: no/ mild pain and moderate/severe pain. Through medical and nursing clinical records, a set of clinical data was collected.
RESULTS: The analysis was performed on 68 patients. The median age was 32.1 years, osteogenesis imperfecta was present in 72.1 % of cases and the median pain score was 2. Logistic regression showed that the independent risk factors of pain were age with a 5 % increase in risk for each year of age (p value = 0.010), a previous surgical intervention (OR = 10.16; CI95%: 2.07-49.89) and the presence of muscle anomalies (OR = 5.91; CI95% 1.09-31.88). The median pain score in the osteogenesis imperfecta group was 1, whereas in the other group it was 2, with a non-significant difference.
CONCLUSIONS: In genetic metabolic bone diseases, pain is a relevant symptom. Increased age, surgical intervention and the presence of muscular problems are risk factors in determining higher levels of pain and require targeted treatments.
DESIGN: Retrospective cohort study.
SETTING: The patients were recruited through the outpatient register of the Centre for Rare Skeletal Diseases between 2017 and 2022 from a dedicated orthopedic hospital in northern Italy.
SUBJECTS: All patients with a diagnosis of genetic metabolic bone disease were enrolled. The diagnosis of the pathology was based on the clinical data and the outcome of any genetic tests.
METHODS: Pain intensity (0-10) at the first exam was collected and two comparison groups were made: no/ mild pain and moderate/severe pain. Through medical and nursing clinical records, a set of clinical data was collected.
RESULTS: The analysis was performed on 68 patients. The median age was 32.1 years, osteogenesis imperfecta was present in 72.1 % of cases and the median pain score was 2. Logistic regression showed that the independent risk factors of pain were age with a 5 % increase in risk for each year of age (p value = 0.010), a previous surgical intervention (OR = 10.16; CI95%: 2.07-49.89) and the presence of muscle anomalies (OR = 5.91; CI95% 1.09-31.88). The median pain score in the osteogenesis imperfecta group was 1, whereas in the other group it was 2, with a non-significant difference.
CONCLUSIONS: In genetic metabolic bone diseases, pain is a relevant symptom. Increased age, surgical intervention and the presence of muscular problems are risk factors in determining higher levels of pain and require targeted treatments.